IL-12/23 Inhibitors and Their Potential Benefits and Risks for Psoriasis Patients

Background Interleukin (IL)-12 and IL-23 are implicated in the pathogenesis of psoriasis and new IL-12/23 inhibitors are currently being studied for psoriasis treatment. Objective To review the literature and provide an update on the current use of anti-IL-12/IL-23 therapies for psoriasis, with special emphasis on risks and benefits. Methods A PubMed search was performed to identify articles in English with key words “Ustekinumab and psoriasis,” “IL-12 and IL-23 and psoriasis,” “ABT-874 and psoriasis,” “IL-12/23 monoclonal antibody,” “IL-12/23 antibody” and “CNTO-1275.” Supplemental methods included Google Scholar, article reference lists and scholarly posters. Results Anti-IL-12/23 therapies may be more effective for psoriasis treatment than concurrent biologics. However, there is a potential risk of compromising cancer surveillance mechanisms through blocking IL-12. Limitations More research is needed into the long-term effects of anti-IL-12/23 agents. Conclusions Convenient dosing of ustekinumab and greater efficacy make the anti- IL-12/23 agents a promising therapeutic option.